OncoSynergy’s cancer drug OS2966 gets FDA orphan drug status

US-based biotechnology firm OncoSynergy has received orphan drug designation from the FDA’s Office of Orphan Products Development (OOPD) for OS2966, a first in class humanized monoclonal antibody, to treat ovarian cancer.

Category One, Showcase, status, Uncategorized, What's Hot